Moderna Expects $18.4 Billion in Sales from Its COVID-19 Vaccine This Year

by Rishma Parpia

Published March 21, 2021 | Business, Pharma

Moderna, Inc. expects to generate $18.4 billion from sales of its experimental mRNA-1273 COVID-19 vaccine being distributed in the U.S. under an Emergency Use Authorization (EUA) granted by the Food and Drug Administration (FDA). This will be the first time that the U.S. based pharmaceutical company will make a profit since it was established in 2010.¹

Moderna Begins Trials for a Booster Shot for South African SARS-COV-2 Variant

Reports of Moderna’s profit projections comes right after the company announced that it had shipped doses of a new variant-specific COVID-19 vaccine, known as mRNA-1273.351, to the National Institutes of Health (NIH). The new vaccine is designed to provide protection against the South African coronavirus strain B.1.351.² This clinical trial will be conducted and funded by the

NIH’s National Institute of Allergy and Infectious Diseases (NAID).³

The South African coronavirus strain vaccine is ready to be tested in a Phase 1 clinical trial and is intended to be used as a third dose booster vaccine. The company has said that its two-dose mRNA-1273 vaccine provides neutralizing activity against variant coronavirus strains that cause COVID-19, but would like to evaluate booster doses of the vaccine to increase neutralizing immunity against different virus variants.⁴

Moderna CEO Stephane Bancel said:

Moderna is committed to making as many updates to our vaccine as necessary until the pandemic is under control. We hope to demonstrate that booster doses, if necessary, can be done at lower dose levels, which will allow us to provide many more doses to the global community in late 2021 and 2022 if necessary.⁵

Moderna to Produce 700 Million Doses of Its COVID-19 Vaccine

Moderna has said that it expects to manufacture at least 700 million doses of COVID-19 vaccine this year and 1.4 billion doses in 2022. The company has a business contract with the federal government for 300 million doses and has distributed 55 million doses in the U.S.⁶

Currently, each vial of Moderna’s mRNA COVID-19 vaccine contains ten doses, which is enough to fully vaccinate five people; however, the company has submitted a proposal to the FDA to fill its COVID-19 vaccine vials with up to five additional doses to reduce the backlog in the manufacturing process.^{7 8}Moderna charges $30 for the required two shots in the U.S and $36 in the European Union.⁹

The company is also in negotiations with the World Health Organization’s (WHO) COVAX initiative to supply doses of the COVID-19 vaccine to developing countries this year and in 2022.¹⁰

---

If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.

Click here to view References:

  COVAX, COVID-19, Emergency Use Authorization, EUA, FDA, Food and Drug Administration, Moderna, mRNA-1273.351, National Institute of Allergy and Infectious Diseases, National Institutes of Health, National Vaccine Information Center, NIAID, NIH, NVIC, Rishma Parpia, Stéphane Bancel, The Vaccine Reaction, WHO, World Health Organization